Adam King - 03 Mar 2022 Form 4 Insider Report for QSAM Biosciences, Inc. (QSAM)

Role
Chief Financial Officer
Signature
/s/ Adam King
Issuer symbol
QSAM
Transactions as of
03 Mar 2022
Transactions value $
$0
Form type
4
Filing time
29 Jun 2023, 06:14:22 UTC
Next filing
02 May 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction QSAM Common Stock Award $0 +20,910 $0 20,910 23 Jun 2023 Direct F1
transaction QSAM Common Stock Award +2,040 +9.8% 22,950 23 Jun 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction QSAM Options to buy common stock Award $0 +12,500 $0 12,500 03 Mar 2022 Common Stock 12,500 $10 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This award of shares is being made pursuant to the Issuer's restricted stock award agreement and is subject to a vesting schedule, such that a portion or all of this award of restricted stock may be forfeited in the future if certain milestones are not met.
F2 Shares acquired upon conversion of deferred salary of $10,200.
F3 As of 3/31/2023, 9,375 shares vested based on performance. The balance of the shares will vest in 36 monthly installments commencing March 1, 2023.